Asthma Therapy
Asthma patients can be effectively and safely treated with high-dose budesonide/formoterol
Published in Respiratory Therapeutics Week, June 12th, 2006
"Budesonide/formoterol 160/4.5 mc g, two inhalations bd, is an effective and well-tolerated maintenance therapy for patients not controlled on inhaled corticosteroids alone. The authors assessed the efficacy and safety of a higher dose of budesonide/formoterol in patients with persistent symptomatic asthma. This was a 24-week, double-blind, double-dummy randomized study," scientists in Australia report.
C. Jenkins and colleagues, Woolcock Institute of Medical Research, explained, "Budesonide/formoterol 320/9...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Respiratory Therapeutics Week
More Articles from Respiratory Therapeutics Week
- Pediatric Asthma
Study suggests spacers have advantages over nebulizers for childhood asthma - Respiratory Medicine
Early occupational exposure can affect lungs later - Respiratory Medicine
Nighttime breathing mask also decreases blood pressure in people with sleep apnea - Aspergillosis Diagnostics
MDVI measures therapeutic response to antifungal therapy in invasive pulmonary aspergillosis - Asthma Diagnostics
Asthma and COPD diagnoses may not be improved by GPs performing office spirometry - Business Update
BioProgress announces the OTC launch of sore throat treatment, Collunovar for Dexo France - More from this issue of Respiratory Therapeutics Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
